Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the effects of urapidil on bronchospasm, myocardial hypoxia and postural hypotension in experimental animals. Urapidil dose-dependently inhibited bronchospasm induced by histamine in anaesthetized guinea pigs and the contraction of isolated trachea induced by noradrenaline or phenylephrine. Urapidil markedly delayed the appearance of severe dyspnoea induced by histamine aerosol in guinea pigs. Further, urapidil inhibited isoproterenol-induced ST depression in rats and inhibited histamine-induced ST depression in rabbits. The postural hypotension induced by prazosin was greater than that induced by urapidil in equihypotensive doses in conscious rabbits. Urapidil induced a lesser alpha-blockade in the vein than in the artery compared with prazosin. These combined properties of urapidil suggest that the drug is worth investigation in hypertensive patients with bronchial asthma or ischaemic heart disease.
 ...
PMID:Pharmacological effects of urapidil on bronchospasm, myocardial hypoxia and postural hypotension in experimental animals. 323 Apr 72

Arterial hypertension is a well known risk factor for atherosclerosis and its complications. Lowering of blood pressure significantly reduces the incidence of cerebrovascular events and to a minor extent that of ischemic heart disease. Interference of antihypertensive drugs on lipoproteins, glucose and electrolytes metabolism has been suggested as a hypothesis for the lower than expected protection against cardiac events. The new antihypertensive agents such as calcium antagonists, angiotensin converting enzyme inhibitors and post-synaptic alpha-1 receptor antagonists have proved to be neutral or to have positive effect on metabolic disturbances. Urapidil, a multifactorial antihypertensive agent, has been shown to significantly lower blood pressure and to have a favorable impact on the metabolic profile in adult and elderly hypertensive patients and in patients with diabetes mellitus and elevated blood pressure. Although arterial hypertension is a risk factor for atherosclerosis, the clinical events at the cerebral and coronary levels are secondary to thrombo-embolic complications. On the other hand it has been shown that abnormalities in coagulation factor has a prognostic value. Therefore, new and old antihypertensive agents should be investigated not only for their effects on hypertension, metabolic profile and quality of life but also on coagulation, in order to improve the therapeutic profile.
 ...
PMID:Modification of cardiovascular risk factors during antihypertensive treatment: current and new approach trends. The urapidil experience. 780 13

Hypertensive crisis is defined as an acute elevation of the blood pressure involving the risk of life. Agents used to the treatment of hypertensive emergencies should lower the blood pressure under control and produce minimal adverse effect. The aim of this study was to evaluate the antihypertensive efficacy of urapidil i.v. in hypertensive emergencies. Twenty three patients (pts) with the hypertensive crisis in association with ischaemic heart disease and/or acute left ventricular failure were studied. Urapidil was given intravenously in the emergent treatment to the group of 23 pts in the mean dose of 50 mg. Systolic (RRs) diastolic blood pressure (RRd) and heart rate were measured within 4 hours after the drug administration. In this group of pts the significant decrease in RRs and RRd after 2 min. of administration of urapidil was observed and the maximum effect (p < 0.05) occurred within 40 min. The heart rate decreased by 8% and was significantly different (p < 0 > 05) at the maximum point of the drug action. Urapidil administered in 25-75 mg i.v. appeared an effective antihypertensive agent in more than 90% of patients with hypertensive emergencies. What was striking, no reflex tachycardia was observed after i.v. administration of urapidil despite its antihypertensive action.
 ...
PMID:[Evaluation of the antihypertensive efficacy of urapidil in the treatment of hypertension emergencies]. 861 14